Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 2
Submit an article Journal homepage
73
Views
23
CrossRef citations to date
0
Altmetric
Research Article

Production of Proangiogenic Cytokines During Thalidomide Treatment of Multiple Myeloma

Anna Dmoszyńska Department of Haematology, University School of Medicine, Jaczewskiego 8, 20-950, Lublin, Poland
,
Agnieszka Bojarska-Junak Department of Clinical Immunology, University School of Medicine, Jaczewskiego 8, 20-950 Lublin, Poland
,
Damian Domański Department of Clinical Immunology, University School of Medicine, Jaczewskiego 8, 20-950 Lublin, Poland
,
Jacek Roliński Department of Clinical Immunology, University School of Medicine, Jaczewskiego 8, 20-950 Lublin, Poland
,
Marek Hus Department of Haematology, University School of Medicine, Jaczewskiego 8, 20-950, Lublin, Poland
&
Maria Soroka-Wojtaszko Department of Haematology, University School of Medicine, Jaczewskiego 8, 20-950, Lublin, Poland
Pages 401-406 | Published online: 01 Jul 2009

  • Anderson, K.C., Hamblin, T.J. and Taylor, A. (1999) "Management of multiple myeloma today", Sem. Hemat. 36, 3-8.
  • Aguayo, A., Estey, B. and Kantarjian, H. (1999) "Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia", Blood 94, 3717-3721.
  • Aguayo, A., O'Brien, S. and Keating, M. (2000) "Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia", Blood 96, 768-770.
  • Aguayo, A., Kantarjian, H., Manshouri, T., Gidel, C., Estey, E., Thomas, D., Koller, C., Estrov, Z., O'Brien, S., Keating, M., Freireich, E. and Albitar, M. (2000) "Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes", Blood 96, 2240-2245.
  • Barlogie, B. (2000) Thalidomide (T) in the Management of Multiple Myeloma (MM): The Arkansas Experience in >(300) Patients with single agent and combination chemotherapy. Proceedings of ASCO 19, 9A.
  • Bataille, R., Jourdan, M., Zhang, X.G. and Klein, B. (1989) "Serum levels of interleukin 6--a potent myeloma growth factor, as a reflect of disease severity in plasma cell dyscrasia", Invest 84, 2008-2011.
  • D' Amato, R.J., Loughman, M.S., Flyrn, E. and Folkman, J. (1994) "Thalidomide is an inhibitor of angiogenesis", Proc. Natl. Acad. Sci. USA 91, 4082-4085.
  • Dmoszynska, A. (2000) 'Thalidomide--a new possibilities of treatment for patients with multiple myeloma", Acta Haemat. Pol. 31, 5-9.
  • Ellis, L.M. and Fidler, I.J. (1996) "Angiogenesis and metastasis", Eur. J. Cancer 32A, 2451.
  • Ferrara, N. (1996) "Vascular endothelial growth factor", Eur. J. Cancer 32A, 2413.
  • Folkman, J., Shing, Y. and Angiogenesis (1992), J. Biol. Chem. 267, 10931-10934.
  • Folkman, J. (1995) "Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis", N. Eng. J. Med. 333, 1757-1763.
  • Fuhrmann-Benzakein, E., Ma, M.N. and Rubbia-Brandt, L. (2000) "Elevated levels of angiogenic cytokines in the plasma of cancer patients", Int. J. Cancer 85, 40-45.
  • Haslett, P.A.J., Corral, L.G., Albert, M. and Kaplan, G. (1998) "Thalidomide costimulates human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset", J. Exp. Med. 187, 1885-1892.
  • Joensuu, H., Salven, P., Teerenhovi, L. and Orpana, A. (2000) "Concomitant elevation of serum VEGF and bFGF i strongly associated with poor outcome in non-Hodgkin's lymphoma", Proceedings of ASCO 19, 15a.
  • Jourdan, M., Tarte, K., Legouffe, E.M., Brochier, J., Rossi, J.F. and Klein, B. (1999) "Tumor necrosis factor is a survival and proliferation factor for human myeloma cells", Eur. Cytokine Netw. 10, 65-70.
  • Montesano, R., Vassalli, I.D., Baird, A., Guillemin, R. and Orci, L. (1986) "Basic fibroblast growth factor induces angiogenesis in vitro", Proc. Natl. Acad. Sci., USA 83, 7297.
  • Neben, K., Moehler, T., Egerer, G., Kraemer, A., Hillengass, J., Benner, A., Ho, A.D. and Goldschmidt, H. (2000) "High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma", Blood 96, 167a.
  • Raje, N. and Anderson, K. (1999) "Thalidomide--a revival story", N. Eng. J. Med. 341, 1606-1608.
  • Salven, P., Teerenhovi, L. and Joensuu, H. (1997) "A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma", Blood 90, 3167-3172.
  • Smith, B.D., Smith, G.L., Sasaki, C.T. and Huffty, B.G. (2000) "Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma", J. Clin. Oncol. 18, 2046-2052.
  • Vacca, A., Ribatti, D. and Presta, M. (1999) "Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase 2 secretion parallel progression of human multiple myeloma", Blood 93, 9064-9074.
  • Weber, D.M., Rankin, K., Gavino, M., Delasalle, K., Agnayo, A., Albitar, M. and Alexanian, R. (2000) "Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma. Abstracts of 42th ASH Meeting", Blood 96(1), 719a.
  • Yoshikawa, T., Tsuburaya, A., Kobayashi, O., Sairenji, M., Motohashi H., Yanoma, S. and Noguchi, Y. (2000) "Plasma concentrations of VEGF and bFGH in patients with gastric carcinoma", Cancer Lett. 153, 7-12.
  • Zdzisinska, B., Walter-Croneck, A., Dmoszynska, A., Rzeski, W., Paduch, R., Szuster-Ciesielska, A. and Kandefer-Szerszen, M. (2000) "Bone marrow stromal cells of patients with multiple myeloma (MM) produce more proinflammatory cytokines", Immun. Lett. 73, 251.
  • Zeldis, J.B., Williams, B.A., Thomas, D. and Elsayed, M.E. (1999) "A comprehensive program for controlling and monitoring access to thalidomide", Clin. Ther. 21, 319-330.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.